Celiac Disease Testing Insurance Denied? How to Appeal

Celiac disease affects roughly 1 in 100 people worldwide yet remains dramatically underdiagnosed — partly because insurance barriers delay or block the testing needed to confirm the diagnosis. If your insurer denied coverage for celiac serologic testing (ICD-10: K90.0), small bowel biopsy, or HLA genetic typing, you have strong grounds for appeal. The American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG) publish clear, evidence-based guidelines establishing when celiac testing is indicated, and denials that contradict those guidelines are frequently overturned when the right documentation is presented.

Why Insurers Deny Celiac Disease Testing

• "Not medically necessary" for serology: Insurers deny celiac serology when they determine there is insufficient clinical justification — a position that ignores the broad indications recognized by both the AGA and ACG. Established indications include chronic diarrhea, unexplained iron-deficiency anemia (ICD-10: D50.9), unexplained weight loss, dermatitis herpetiformis (ICD-10: L13.0), first-degree relatives of confirmed celiac patients, Type 1 diabetes (ICD-10: E10), autoimmune thyroid disease, elevated transaminases without other cause, and osteoporosis without clear etiology.

• "Biopsy not required after positive serology": Some insurers deny the confirmatory small bowel biopsy (CPT 43239) even after positive blood tests, treating serology as sufficient for diagnosis. Current ACG and AGA guidelines require histologic confirmation via duodenal biopsy before initiating a lifelong gluten-free diet — serology alone is not sufficient for a definitive diagnosis.

• "Gluten challenge testing not covered": If you were already following a gluten-free diet when testing was ordered, a gluten challenge is clinically required to restore the accuracy of serologic and biopsy results. Denials of repeat testing after a gluten challenge ignore that the challenge is a clinical necessity for a valid diagnosis.

• "HLA genetic testing not medically necessary": HLA-DQ2 and HLA-DQ8 typing (CPT 81381/81382) is indicated for patients unable to tolerate a gluten challenge, for ruling out celiac in first-degree relatives, and for evaluating seronegative cases with ongoing clinical suspicion. These indications are documented in both AGA and ACG guidelines.

• "Documentation insufficient": Clinical records do not adequately support the indication — presenting symptoms, prior lab results, or duration of symptoms are not documented in sufficient detail for the insurer's criteria.

• Out-of-network or coding error: The lab or endoscopy center was out of network, or the claim was submitted with incorrect CPT or ICD-10 codes that triggered an automatic denial.

How to Appeal Celiac Disease Testing Denials

Step 1: Obtain the Denial in Writing and Request the Clinical Policy Bulletin

Your denial letter must state the specific criteria used and your appeal deadline — typically 180 days for commercial plans under ERISA §1133. Request the insurer's clinical policy bulletin for celiac disease testing. Compare it against the AGA and ACG celiac disease clinical guidelines. Where the insurer's criteria are more restrictive than published guidelines, document the discrepancy explicitly in your appeal letter.

Step 2: Have Your Gastroenterologist Write a Detailed Letter of Medical Necessity

The physician letter should include: your diagnosis or suspected diagnosis with specific ICD-10 codes (K90.0 for confirmed celiac disease; K90.4 for malabsorption, unspecified; D50.9 for iron-deficiency anemia; L13.0 for dermatitis herpetiformis); presenting symptoms with duration; relevant prior lab results (iron studies, CBC, liver enzymes, thyroid function); a direct citation to AGA or ACG guidelines establishing the clinical indication for the specific test requested; and an explanation of why the diagnosis cannot be confirmed without the requested test.

Step 3: Use Precise Diagnostic and Procedure Codes

Specific ICD-10 and CPT codes strengthen your appeal by demonstrating clinical precision. For serology: tTG-IgA (CPT 86200), total IgA (CPT 82784), deamidated gliadin peptide IgA/IgG (CPT 86255). For small bowel biopsy: upper endoscopy with biopsy (CPT 43239), paired with ICD-10 K90.0 or K90.4. For HLA typing: CPT 81381/81382, with clinical indication documented as negative serology with persistent clinical suspicion or evaluation of a first-degree relative of a confirmed celiac patient.

Step 4: Build a Coherent Clinical Narrative

Explain what symptoms prompted the investigation, how long they have been present, what diagnoses have been considered or excluded, and why celiac disease is being evaluated. A coherent clinical story — connecting your symptoms to the recognized indications for testing — makes it significantly harder for the insurer to sustain a "not medically necessary" position. If prior lab results show IDA, low ferritin, or elevated liver enzymes, include these specifically as they are recognized celiac indications in both AGA and ACG guidelines.

Step 5: Cite Federal Protections Under ACA and ERISA

For ACA-compliant plans, laboratory services and outpatient care are essential health benefits under ACA §2719. Medically necessary diagnostic testing for a recognized clinical indication cannot be categorically excluded. For employer-sponsored plans, ERISA §1133 guarantees the right to appeal and to receive a written denial citing the specific criteria applied.

Step 6: Submit and Escalate if Needed

Send via certified mail and through the insurer's member portal. Keep copies with delivery confirmation. If the internal appeal is denied, request External Independent Review: Complete Guide" class="auto-link">external review immediately — specifically by a gastroenterologist. External reviews overturn insurer denials in 40–60% of cases when clinical guideline support is clearly documented.

What to Include in Your Appeal

• Denial letter with the specific reason code and policy provision cited
• Physician letter of medical necessity with ICD-10 codes and specific AGA/ACG guideline citations
• Office visit notes documenting symptoms and their duration
• Prior lab results (CBC, iron studies, metabolic panel, liver enzymes, thyroid function)
• Any prior positive serologic results if appealing a biopsy denial
• AGA or ACG celiac disease guideline excerpt establishing the clinical indication for the requested test
• HLA clinical rationale letter (if contesting HLA testing denial) explaining the specific indication
• Insurer's clinical policy bulletin with your documented analysis of where it diverges from AGA/ACG standards

Fight Back With ClaimBack

Celiac disease testing denials routinely contradict ACG and AGA guidelines that explicitly establish the need for serology, biopsy, and in specific cases HLA typing. A properly documented appeal citing these guidelines and connecting your clinical presentation to the recognized indications wins a significant percentage of these denials. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal